title: A Contemporary Approach to Pulmonary Arterial Hypertension.
abstract: In recent years, there have been major changes in the landscape of pulmonary arterial hypertension therapy with the introduction of novel agents and innovative treatment strategies for this progressive disease. The aim of this review is to discuss the evolution in trial design in this field and highlight the salient features of recently published studies. We also summarize our approach to therapy selection in this chronic disease and identify areas for future exploration. The therapeutic armamentarium now includes 13 approved therapies. While most of these agents have been studied in small, short-term trials using the 6-min walk distance as a primary endpoint, there has been a shift in recent years toward larger, long-term, event-driven trials that utilize combined morbidity and mortality endpoints. The SERAPHIN and GRIPHON trials were two such studies, which led to the approval of the dual endothelin-receptor antagonist macitentan and the selective prostacyclin receptor antagonist selexipag, respectively. Other event-driven trials, like AMBITION and COMPASS-2, have provided valuable insight into the use of combined oral therapies in symptomatic patients. In conclusion, despite being a more manageable disease in the modern treatment era, pulmonary hypertension is still associated with considerable morbidity and much more work remains to be done in this field. Important questions remain about the most optimal way to manage patients and conduct trials going forward.
authors: Division of Cardiology, Department of Internal Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, 520 East 70th Street, New York, NY, 10021, USA. udk9001@nyp.org.
authors: Udhay
authors: U
authors: Krishnan
authors: Division of Cardiology, Department of Internal Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, 520 East 70th Street, New York, NY, 10021, USA.
authors: Evelyn M
authors: EM
authors: Horn
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011719:Pyrazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D011719:Pyrazines; D011743:Pyrimidines; D013449:Sulfonamides; C523468:selexipag; C533860:macitentan
keywords: Combination therapy; Hospitalizations; Mortality; Prostacyclins; Pulmonary hypertension; Six-minute walk distance